Monte Rosa Therapeutics announced data for MRT-8102, its NEK7-directed molecular glue degrader, showing positive impact on biomarkers linked to atherosclerotic cardiovascular disease
BiotechTV - News
00:00
Intro
BiotechTV introduces Markus Warmuth and Monte Rosa Therapeutics from the company’s Basel offices, with support from the Basel Area Life Sciences Supercluster.
Play episode from 00:00
Transcript
